Anti-osteoporotic and Antioxidant Activities by Rhizomes of *Kaempferia parviflora* Wall. ex Baker

Nguyen Phuong Thao^{1, 2}, Bui Thi Thuy Luyen¹, Sang Hyun Lee³, Hae Dong Jang^{3,*}, and Young Ho Kim^{1,*}

¹College of Pharmacy, Chungnam National University, Daejeon 305-764, Republic of Korea ²Institute of Marine Biochemistry (IMBC), Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Cau Giay, Hanoi, Vietnam

³Department of Food and Nutrition, Hannam University, Daejeon 305-811, Republic of Korea

Abstract – In this report, we investigated the antioxidant (peroxyl radical-scavenging and reducing capacities) and anti-osteoporotic activities of extracts and isolated constituents (1 - 16) from the rhizomes of *Kaempferia parviflora* Wall. ex Baker on pre-osteoclastic RAW 264.7 cells. Compound 5 exhibited significant peroxyl radical-scavenging capacity, with TE value of $8.47 \pm 0.52 \mu$ M, while compound 13 showed significant reducing capacity, with CUPRAC value of $5.66 \pm 0.26 \mu$ M, at 10.0μ M. In addition, flavonoid compounds 2, 4, 6, 8, 10, 12, and terpene compound 15 showed significant inhibition of tartrate-resistant acid phosphatase (TRAP) in NF- κ B ligand-induced osteoclastic RAW 264.7 cells, with values ranging from 16.97 ± 1.02 to $64.67 \pm 2.76\%$. These results indicated that *K. parviflora* could be excellent sources for the antioxidant and anti-osteoporotic traditional medicinal plants.

Keywords - Kaempferia parviflora, Zingiberaceae, Antioxidant, Anti-osteoporosis, TRAP

Introduction

Natural antioxidant compounds have numerous beneficial health effects. Previous studies suggested that antioxidants reduce the risk of chronic diseases, including cancer and heart diseases, as well as cardiovascular and cerebrovascular events. Several antioxidants have been reported including anthocyanins, flavonoids, phenolic acids, and tanins.¹ These compounds act as radical scavengers, hydrogen donors, electron donors, and metal-chelating agents that can detoxify reactive oxygen species (ROS) and reduce ROS induced damage. Antioxidant activity is generally due to the trapping of free radicals.² In addition, antioxidant systems play important roles in the development of osteoporosis. Evolving evidence suggests that ROS are involved in osteogenesis, including bone formation and resorption, which are associated with the aging process and may lead to osteoporosis. Osteoporosis is a family of disorders in which systemic bone mass is reduced and the

*Author for correspondence

Prof. Young Ho Kim, College of Pharmacy, Chungnam National University, Daejeon 305-764, Korea

Tel: +82-42-821-5933; E-mail: yhk@cnu.ac.kr

patient is at risk of spontaneous fracture. Bone development is a normal process that involves the resorption of bone by osteoclasts and the synthesis of bone matrix by osteoblasts.³

Kaempferia parviflora Wall ex. Baker (Black galingale), known locally in Thai as Kra-Chai-Dam, is an herbaceous plant in the Zingiberaceae. Traditionally, its black to purple rhizomes are used in local food as a flavoring agent and as a traditional medicinal plant for the treatment of a wide spectrum of illnesses. Since ancient times, it has traditionally been used as a health-promoting and vitalizing agent, and a folk medicine to lower blood glucose levels, improve blood flow, and increase vitality.⁴ The effects of K. parviflora rhizomes on male sexual function have also been promoted. Several studies have examined the chemical constituents of K. parviflora and their biological activities. Flavonoids, attached with many methoxyl groups, are demonstrated as the major constituents,⁵ along with chalcone derivatives, related phenolic compounds, and kaempferiaosides.⁶ Recently, extracts of this plant and compounds isolated from them, including flavonoids have been reported to exert various pharmacological activities, such as inhibition of α -glucosidase,⁷ cholinesterase,⁸ Pglycoprotein,⁹ and NO production,¹⁰ as well as the ability to reduce obesity,¹¹ inflammatory,¹² allergic,¹³ and convul-

Prof. Hae Dong Jang, Department of Food and Nutrition, Hannam University, Daejeon 305-811, Korea

Tel: +82-42-629-8805; E-mail: haedong@hnu.kr

Natural Product Sciences




Fig. 1. Chemical structures of compounds 1 - 16 from K. parviflora (Glc: glucosyl).

sions,¹⁴ and treatment of plasmodial, fungal, and mycobacterial infections.⁴ *K. parviflora* extracts have also been shown to modulate the function of multidrug resistance associated-proteins,¹⁵ and induce cytotoxicity in various cancer cell lines.¹⁶

In our screening study of medicinal plants on antioxidant and anti-osteoporotis activities, the methanolic extract of *K. parviflora* exhibited significant antioxidant and antiosteoporosis properties. This study details anti-oxidative evaluation of extracts and constituents isolated from *K. parviflora* (1 - 16, see Fig. 1) determined using the oxygen radical absorbance capacity (ORAC) and cupric ion reducing antioxidant capacity (CUPRAC) assays. In addition, the anti-osteoporosis activity of these compounds were evaluated through their inhibitory effects on the osteoclast differentiation from RAW 264.7 pre-osteoclast cells.

Experimental

Plant material – The rhizomes of *Kaempferia parviflora* Wall. Ex Baker were kindly provided from Ok Nam Kim, which was purchased from a local shop, Laos, in 2014, and identified by Prof. Young Ho Kim, College of Pharmacy, Chungnam National University. A voucher specimen (CNU-14110) was deposited at the Herbarium of the College of Pharmacy, Chungnam National University, Republic of Korea.

Compounds – From the methanolic extracts of the rhizomes of *K. parviflora* sixteen compounds (**1** - **16**) were isolated and structurally elucidated. Stock solutions of tested compounds in DMSO were prepared, kept at -20 °C, and diluted to the final concentration in fresh media before each experiment. For not to affect cell growth, the final DMSO concentration did not exceed 0.5% in all experiments.

Chemicals and reagents – 2,2'-Azobis (2-amidinopropane) dihydrochloride (AAPH), neocuproine, Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), β -glycerophosphate, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Triton X-100, Hank's balanced salt solution (HBSS), RANKL, leukocyte acid phosphatase assay kit, sodium tartrate, *p*-nitrophenylphosphate (PNPP), phosphate-buffered saline (PBS, pH 7.4), dihydroethidium dihydrorhodamine (DHR), and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). RAW 264.7 cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The natural compounds tested in this study were isolated from Library of Natural Products, College of Pharmacy, Chungnam National Uni-

versity. Information about their isolation method, chemical structure, and purity provided in references listed in main text. All solvents were used of analytical grade and supplied by SK Chemicals (Ulsan, Korea).

General experimental procedures - Optical rotations were determined on a JASCO P-2000 polarimeter. The UV spectrum was recorded on a JASCO V-630 spectrophotometer. IR spectra were obtained on a Bruker TENSOR 37 FT-IR spectrometer. The NMR spectra were recorded on a JEOL ECA 600 MHz and JEOL JNM-AL 400 MHz spectrometer and TMS was used as an internal standard, chemical shift (δ) was expressed in ppm with reference to the TMS signals. Column chromatography (CC) was performed on silica gel (Kieselgel 60, 70 - 230 mesh and 230 - 400 mesh, Merck), porous polymer gel (Diaion[®] HP-20, 70 × 180 mm, Mitsubishi Chemical), SephadexTM LH20, octadecyl silica (ODS, Cosmosil 140 C18-OPN, Nacalai Tesque), and YMC RP-18 resins (30 -50 µm, Fuji Silysia Chemical). Thin layer chromatography (TLC) used pre-coated silica gel 60 F_{254} (1.05554.0001, Merck) and RP-18 F₂₅₄₈ plates (1.15685.0001, Merck) and compounds were visualized by spraying with aqueous 10% H₂SO₄ and heating for 3 - 5 minutes.

Extraction and isolation – The rhizomes of K. parviflora Wall. ex Baker were dried at room temperature. The dried material (0.8 kg) was extracted with MeOH using ultrasonic maceration $(3 \times 2.5 \text{ h})$ at 35 °C, after which the solutions were filtered, the combined filtrates were concentrated under reduced pressure to give a crude extract. After concentration, the MeOH extract (18.26 g, M) was suspended in H₂O and then partitioned successively with CH₂Cl₂ to give CH₂Cl₂ fraction (10.03 g, C) and water layer (8.20 g, W), respectively. Fraction C was chromatographed over silica gel, eluted with n-hexane in acetone ($0 \rightarrow 100\%$, stepwise), yielding six fractions (C-1 to C-6). Fraction C-2 (1.85 g) was chromatographed over a silica gel column eluted with *n*-hexane-acetone (9:1) and further purified by YMC RP-18 CC using MeOH-H₂O (4:1) as the eluent to afford 5-hydroxy-3,7-dimethoxyflavone (3, 56.8 mg), 5-hydroxy-3,7,3',4'-tetramethoxyflavone (11, 52.5 mg), 2-methoxyanthraquinone (13, 4.2 mg), 2-hydroxy-9,10-anthraquinone (14, 5.1 mg), and β sitosterol (15, 5.8 mg). Next, fraction C-3 (0.9 g) was chromatographed over a silica gel CC eluted with CH2Cl2-MeOH (17:1) to obtain 5-hydroxy-7-methoxyflavone (1, 27.5 mg), 5-hydroxy-7,4'-dimethoxyflavone (7, 25.6 mg), and 5-hydroxy-3,7,4'-trimethoxyflavone (9, 57.3 mg). Similarly, fraction C-4 (1.2 g) was separated by YMC RP-18 chromatography using acetone-H₂O (2:1) and SephadexTM LH-20 using CH₂Cl₂-MeOH (1:1) as eluent to give 5,7-

dimethoxyflavone (2, 75.5 mg), 3,5,7-trimethoxyflavone (4, 20.9 mg), 5,7,4'-trimethoxyflavone (6, 8.6 mg), and 3,5,7,3',4'-pentamethoxyflavone (10, 55.6 mg). Next, fraction C-5 (1.32 g) was chromatographed on a column of SephadexTM LH-20 and eluted with H₂O and MeOH, successively, to give three subfractions (C-5.1 to C-5.3). Subfraction C-5.1 (0.4 g) was separated by YMC RP-18 CC, using MeOH-H₂O (3:1) as eluent, and further purified by over silica gel CC, eluted with CH₂Cl₂-MeOH (10:1), to obtain 4'-hydroxy-5,7-dimethoxyflavone (5, 52.8 mg) and daucosterol (16, 4.5 mg). Finally, subfraction C-5.2 (0.5 g) was separated by CC over silica gel, using CH₂Cl₂-MeOH-H₂O (8:1:0.1) as eluents, and further purified by YMC RP-18 CC, eluted with MeOH-H₂O (3:1), to give 3,5,7,4'-tetramethoxyflavone (8, 8.6 mg), and 4',5dihydroxy-3,7,4'-trimethoxyflavone (12, 10.5 mg).

Cupric ion reducing antioxidant capacity (CUPRAC) assay – The electron-donating capacities of each compound to reduce Cu(II) to Cu(I) ions were assessed according to the method of Aruoma *et al.*¹⁷ Forty microliters of different concentrations of each compound dissolved in ethanol were mixed with 160 μ L of a mixture containing 0.5 mM CuCl₂ and 0.75 mM neocuproine; a Cu(I) ions specific chelator, in 10.0 mM phosphate buffer, pH 7.4. Absorbance was measured using a microplate reader at 454 nm for 1 h. Increased absorbance of the reaction mixture indicated greater reducing power.

Oxygen radical absorbance capacity (ORAC) assay -The ORAC assay, which has been employed extensively in previous antioxidant studies,¹⁸ was carried out using a Tecan GENios multifunctional plate reader (Salzburg, Austria) with fluorescent filters (excitation wavelength: 485 nm, emission filter: 535 nm). In the final assay mixture, fluorescein (40.0 nM) was used as a target of free radical attack with AAPH (20.0 mM) as a peroxyl radical generator in the peroxyl radical-scavenging capacity assay.¹⁸ The analyzer was programmed to record fluorescein fluorescence every 2 min after AAPH had been added. All fluorescence measurements were expressed relative to the initial reading. Final values were calculated based on the difference in the area under the fluorescence decay curve between the blank and test samples. All data were expressed as net protection area (net area). Trolox (1.0 µM) was used as the positive control to scavenge peroxyl radicals. It was used as a control standard and prepared fresh daily. The ORAC value was calculated by dividing the area under the sample curve by the area under the Trolox curve, with both areas being corrected by subtracting the area under the blank curve. One ORAC unit was assigned as the net area of protection provided

Natural Product Sciences

by Trolox at a final concentration of $1.0 \,\mu$ M. The area under the curve of the sample was compared to the area under the curve for Trolox, and the antioxidative value was expressed in micromoles of TE per liter.

Cell culture – RAW 264.7 [macrophages (pre-osteoclasts) from BALB/c mouse] cells were cultured in 96-well plates $(1 \times 10^4 \text{ cells/mL})$ containing DMEM supplemented with 10% (v/v) FBS for 2 days. The medium was then replaced with test samples in a differentiation medium containing 50.0 ng/mL RANKL. The differentiation medium was changed every 2 days.

Cell cytotoxicity by MTT assay – RAW 264.7 cells were cultured in 24-well plates $(2 \times 10^4 \text{ cells/mL})$ containing DMEM supplemented with 10% (v/v) FBS and 1% (v/v) antibiotics in a humidied atmosphere of 5% CO₂ at 37 °C for 5 days, washed with PBS, and pretreated with different concentrations $(1.0 - 20.0 \,\mu\text{M})$ of samples to be tested. After 5 days' incubation, MTT reagent was added to each well, and the plate was incubated at 37 °C for 1 h. The medium was removed, and the plate was washed twice with PBS. The intracellular insoluble formazan was dissolved in DMSO. The absorbance of each cell was then measured at 570 nm using an ELISA (Tecan, Salzburg, Austria) reader, and the percentage proliferation was calculated.¹⁹

TRAP staining - RAW 264.7 cells were seeded in 12well plates $(3 \times 10^4 \text{ cells/well})$ containing DMEM medium plus 10% FBS, and the medium was replaced with test samples in differentiation medium containing 50.0 ng/mL RANKL. The differentiation medium was changed every 2 days. After 5 days, the medium was removed, and the cell monolayer was gently washed twice using PBS. The cells were fixed in 3.5% formaldehyde for 10 min and washed with distilled water. The cells were incubated at 37 °C in a humid and light-protected incubator for 1 h in the reaction mixture of a leukocyte acid phosphatase assay kit (Sigma-Aldrich, St. Louis, MO, USA, Cat. No. 387), as directed by the manufacturer. The cells were washed three times with distilled water, and TRAPpositive multinucleated cells containing three or more nuclei were counted under a light microscope.²⁰

TRAP activity – After differentiating the RAW 264.7 cells into osteoclasts for 5 days, the medium was removed, and the cell monolayer was gently washed twice using ice-cold PBS. The cells were fixed in 3.5% formaldehyde for 10 min and ethanol-acetone (1:1) for 1 min. Subsequently, the dried cells were incubated in 50.0 mM citrate buffer (pH 4.5) containing 10.0 mM sodium tartrate and 6.0 mM PNPP. After 1 h incubation,

the reaction mixtures were transferred to new well plates containing an equal volume of 0.1N NaOH. Absorbance was measured at 405 nm using an enzyme-linked immunoassay reader, and TRAP activity was expressed as the percent of the control.²⁰

Statistical analysis – Data were presented as the means \pm standard deviation (SD) of at least three independent experiments performed in triplicate. Statistical analysis was carried out using the SPSS statistical package (SPSS, Chicago, IL, USA) program, and the significances between the control and experimental groups were analysed using Student's *t*-test. Differences were considered to be significant at ${}^*P < 0.05$ and ${}^{**}P < 0.01$.

Result and Discussion

The methanolic extract of K. parviflora was suspended in H₂O and then partitioned sequentially with CH₂Cl₂ to yield CH₂Cl₂ fraction and H₂O layer. All fractions were first evaluated for their antioxidant activity at concentrations of 5.0 µg/mL and 10.0 µg/mL. The MeOH extract as well as CH₂Cl₂ fraction showed antioxidant activities (see Table 1). At 10.0 µg/mL, the ORAC and CUPRAC values were 7.85 ± 0.08 and $3.35 \pm 0.19 \,\mu\text{M}$ fold higher than the protection provide by 1.0 µM of Trolox, respectively. In addition, all fractions were also screened for their anti-osteoporosis activity. The MeOH extract and CH_2Cl_2 fraction (5.0 µg/mL) significantly inhibited with TRAP activities by $51.03 \pm 1.37\%$ and $64.07 \pm 3.58\%$, respectively. Therefore, the CH₂Cl₂ fraction was selected for chemical constituent separation using various chromatographic methods, which yielded 16 compounds (1 - 16).

Extracts of the rhizomes of K. parviflora and its constituents have shown different pharmacological activities,^{4, 8-10, 13-16} although antioxidant activity have been reported well.²¹ The antioxidant activities of the isolated compounds (1 - 16) were measured using ORAC, which is commonly used for antioxidant assessment and provides important information regarding the antioxidant capacity of biological samples. The results showed that polymethoxyflavonoids (1 - 12) exhibited significant antioxidant activities, with ORAC values ranging from 0.79 ± 0.13 to $8.47 \pm$ $0.52 \ \mu\text{M}$ at $10.0 \ \mu\text{M}$ and from 0.02 ± 0.06 to $2.23 \pm$ $0.05 \ \mu\text{M}$ at $1.0 \ \mu\text{M}$ (see Table 1). Among the compounds, 4'-hvdroxy-5,7-dimethoxyflavone (5) showed the highest activity, with an ORAC value of $8.47\pm0.52~\mu\text{M},$ at 10.0 µM. Anthraquinones (13 and 14) exhibited peroxyl radical scavenging capacities with ORAC values of 3.85 ± 0.22 , 7.04 ± 0.33 and 0.79 ± 0.09 , 1.12 ± 0.09 at concentrations of 10.0 and 1.0 µM, respectively. The remaining triterpene

Comps.	Peroxyl radical-scavenging capacity (TE, µM)		Reducing capacity [Copper(I) ions, µM]	
	1.0 µM	10.0 µM	1.0 µM	10.0 µM
1	0.21 ± 0.06	0.94 ± 0.12	0.50 ± 0.17	0.84 ± 0.36
2	ND	1.26 ± 0.10	ND	0.08 ± 0.06
3	1.01 ± 0.04	3.59 ± 0.16	ND	0.80 ± 0.11
4	0.08 ± 0.03	1.11 ± 0.14	0.29 ± 0.30	0.00 ± 0.17
5	2.23 ± 0.05	8.47 ± 0.52	ND	0.17 ± 0.11
6	0.71 ± 0.03	1.51 ± 0.05	ND	0.17 ± 0.11
7	0.05 ± 0.03	1.01 ± 0.04	0.17 ± 0.11	0.17 ± 0.00
8	0.50 ± 0.03	1.01 ± 0.04	0.17 ± 0.11	0.34 ± 0.17
9	0.02 ± 0.06	0.95 ± 0.11	0.34 ± 0.06	0.04 ± 0.11
10	0.17 ± 0.01	0.79 ± 0.13	ND	0.00 ± 0.86
11	0.44 ± 0.14	2.66 ± 0.16	0.29 ± 0.11	1.05 ± 0.11
12	0.27 ± 0.04	1.70 ± 0.17	0.08 ± 0.06	0.00 ± 0.17
13	0.79 ± 0.09	3.85 ± 0.22	0.63 ± 0.06	5.66 ± 0.26
14	1.12 ± 0.09	7.04 ± 0.33	0.29 ± 0.11	1.05 ± 0.11
15	0.03 ± 0.09	1.26 ± 0.10	0.29 ± 0.11	0.34 ± 0.06
16	0.46 ± 0.02	0.01 ± 0.02	ND	ND
CH ₂ Cl ₂ fraction	1.43 ± 0.10	7.85 ± 0.08	0.67 ± 0.17	3.35 ± 0.19
MeOH extract	1.50 ± 0.02	9.11 ± 0.18	0.80 ± 0.13	4.53 ± 0.06

Table 1. Antioxidant activities of the extracts and isolated compounds (1 - 16) from K. parviflora

All data are expressed as the mean \pm SD of three individual experiments.

Values are expressed as µM of TE. ND: Not determined.

One ORAC unit is equivalent to the net protection area provided by 1.0 μ M of Trolox.

(15) and triterpene glycoside (16) showed weak antioxidant activities with ORAC values of 1.26 ± 0.10 , 0.01 ± 0.02 and 0.03 ± 0.09 , 0.46 ± 0.02 at 10.0 and 1.0 μ M, respectively. These results suggest that the peroxyl radical-scavenging capacities of compounds are dependent on the location and number of hydroxyl and methoxy groups in flavonoids and anthraquinones.

The reducing capacities of compounds (1 - 16) were evaluated by the amount of Cu(I) ions reduced with neocuproine, which interacts specically with Cu(I) ions. Reducing capacity appears to be associated with electron transfer, which was a well-established mechanism contributing to antioxidant capacity. At concentration of 10.0 μ M, 2-methoxyanthraquinone (13) showed significant reducing capacities, with CUPRAC value of 5.66 ± 0.26 μ M. Other compounds (1 - 12 and 14 - 16) showed weak or inactive effects at the tested concentrations. The results were not sufficient for discussion regarding the structure– activity relationship of polymethoxyflavonoid and/or other components. However, more studies may be required for the understanding of their selective potential antioxidant activities.

To date, the anti-osteoporosis effects of extracts and/or compounds isolated from *K. parviflora* have not been

reported. Therefore, we assayed the anti-osteoporosis activity of a methanolic extract and dichloromethane fraction on RAW 264.7 cells. The anti-osteoporotic activities of compounds 1 - 16 were evaluated based on the suppression of excessive bone breakdown by osteoclasts. The results showed that flavonoid derivatives 2, 4, 6, 8, 10, 12, and tecpene 15 suppressed osteoclast formation in a dosedependent manner with TRAP values ranging from 16.97 ± 1.02 to 65.67 ± 2.76 (% of control) at concentration of 10.0 µM (see Fig. 2). Among them, compounds 2 and 12 showed the most significant when compared to daidzein used as a positive control, with values of $40.58 \pm 2.28\%$ and $65.67 \pm 2.76\%$, respectively. However, these results could be regarded as inhibitory effects of compounds on cell viability. To address this, the compounds (5.0 to 20.0 µM) were tested for their cytotoxic activity on RAW 264.7 macrophage cells during a fiveday differentiation period. However, no significant cytotoxic effects were observed (data not shown). Thus, these results suggest that 5,7-dimethoxyflavone (2) and 4',5dihydroxy-3,7,4'-trimethoxyflavone (12) possess antiosteoclastogenic activities, but do not affect cell viability.

When compared both anti-osteoporotic and antioxidant activities of **1** - **16**, the significant both TRAP and peroxyl




Fig. 2. Inhibitory effects of compounds 1 - 16 on TRAP activity in RANKL-induced osteoclastic RAW 264.7 cells. TRAP activity was measured from cultures after 5 days of treatment with RANKL and test compounds (10.0 μ M). The treated control was obtained from RAW 264.7 cells cultured with RANKL stimulation and without test compounds. Data are expressed as percentages of the treated control (mean ± SD, n = 3, *P < 0.05 and **P < 0.01 vs TC. C: control, which was not treated; TC: treated control, which was treated with RANKL). Daidzein (10.0 μ M) was use as a positive control (Pos.).

radical scavenging activities were observed in 16 isolated compounds. In addition, there is no correlation between TRAP activity and antioxidant of tested 16 compounds. In other hand, the significant anti-osteoporotic activities of flavonoid derivatives **2**, **4**, **6**, **8**, **10**, and **12** not showing strong antioxidant activities *in vitro* may be attributed to their indirect antioxidant activities by activating the endogenous antioxidant defense system. Therefore, more research may be needed to determine whether the significant anti-osteoporotic activites compound **2**, **4**, **6**, **8**, **10**, and **12** result from indirect antioxidant activity.

As regards its previous studies, the range of the biological activities of the major flavonoid constituents of K. parviflora rhizomes has not yet been fully elucidated. 5,7-Dimethoxyflavone (2) was found to have anti-inflammatory activity.¹² 5-Hydroxy-7-methoxyflavone (1), 3,5,7trimethoxyflavone (4), 5,7,4'-trimethoxyflavone (6), 5hydroxy-3,7,4'-trimethoxyflavone (9), and 3,5,7,3',4'-pentamethoxyflavone (10) were found to protect against Dgalactosamine-induced cytotoxicity in primary cultured mouse hepatocytes.⁶ 3,5,7,4'-Tetramethoxyflavone (8) and 3,5,7,3',4'-pentamethoxyflavone (10) have an effect similar to that of nobiletin, which strongly promotes the differentiation of 3T3-L1 preadipocytes into mature adipocytes via transcriptional activation of peroxisome proliferatoractivated receptor γ (PPAR γ), yet lacks ligand-binding activity.²² The active constituents of the anti-allergic activity of K. parviflora have been identified as 5-hydroxy-7-methoxyflavone (1), 5-hydroxy-7,4'-dimethoxyflavone (7), and 5-hydroxy-3,7,3',4'-tetramethoxyflavone (11).¹³ In addition, 3,5,7,3',4'-pentamethoxyflavone (10) inhibits P- glycoprotein function.⁹ These recent reports concur with our findings suggesting that flavonoid derivatives are the major constituents that contribute to biological effects of *K. parviflora* Wall. ex Baker.

Acknowledgments

This work was supported by research fund of Chungnam National University.

References

Hu, F. B.; Willett, W. C. J. Am. Med. Assoc. 2002, 288, 2569-2578.
Pietta, P. G. J. Nat. Prod. 2000, 63, 1035-1042.

(3) Kong, Y. Y.; Yoshida, H.; Sarosi, I.; Tan, H. L.; Timms, E.; Capparelli, C.; Morony, S.; Oliveira-dos-Santos, A. J.; Van, G; Itie, A.; Khoo, W.; Wakeham, A.; Dunstan, C. R.; Lacey, D. L.; Mak, T. W.; Boyle, W. J.; Penninger, J. M. *Nature* **1999**, *397*, 315-323.

(4) Yenjai, C.; Prasanphen, K.; Daodeeb, S.; Wongpanich, V.; Kittakoop, P. *Fitoterapia* **2004**, *75*, 89-92.

(5) Sutthanut, K.; Sripanidkulchai, B.; Yenjai, C.; Jay, M. J. Chromatogr: A 2007, 1143, 227-233.

(6) Chaipech, S.; Morikawa, T.; Ninomiya, K.; Yoshikawa, M.; Pongpiriyadacha, Y.; Hayakawa, T.; Muraoka, O. *Chem. Pharm. Bull.* **2012**, *60*, 62-69.

(7) Azuma, T.; Kayano, S. I.; Matsumura, Y.; Konishi, Y.; Tanaka, Y.; Kikuzaki, H. *Food Chem.* **2011**, *125*, 471-475.

(8) Sawasdee, P.; Sabphon, C.; Sitthiwongwanit, D.; Kokpol, U. *Phytother. Res.* **2009**, *23*, 1792-1794.

(9) Patanasethanont, D.; Nagai, J.; Yumoto, R.; Murakami, T.; Sutthanut, K.; Sripanidkulchai, B. O.; Yenjai, C.; Takano, M. *J. Pharma. Sci.* **2007**, *96*, 223-233.

(10) Wattanapitayakul, S. K.; Suwatronnakorn, M.; Chularojmontri, L.; Herunsalee, A.; Niumsakul, S.; Charuchongkolwongse, S.; Chansuvanich, N. *J. Ethnopharmacol.* **2007**, *110*, 559-562.

(11) Akase, T.; Shimada, T.; Terabayashi, S.; Ikeya, Y.; Sanada, H.;

Aburada, M. J. Nat. Med. 2011, 65, 73-80.

(12) Wong, C. S.; Tansakul, P.; Tewtrakul, S. J. Ethnopharmacol. 2009, 124, 576-580.

(13) Tewtrakul, S.; Subhadhirasakul, S.; Kummee, S. J. Ethnopharmacol. **2008**, *116*, 191-193.

(14) Wattanapitayakul, S. K.; Chularojmontri, L.; Herunsalee, A.; Charuchongkolwongse, S.; Chansuvanich, N. *Fitoterapia* **2008**, *79*, 214-216.

(15) Patanasethanont, D.; Nagai, J.; Matsuura, C.; Fukui, K.; Sutthanut, K.; Sripanidkulchai, B.O.; Yumoto, R.; Takano, M. *Eur. J. Pharmacol.* **2007**, *566*, 67-74.

(16) Yenjai, C.; Wanich, S. Bioorg. Med. Chem. Lett. 2010, 20, 2821-2823.

(17) Aruoma, O. I.; Deiana, M.; Jenner, A.; Halliwell, B.; Kaur, H.; Banni, S.; Corongiu, F. P.; Dessí, M. A.; Aeschbach, R. *J. Agric. Food Chem.* **1998**, *46*, 5181-5187.

(18) Kurihara, H.; Fukami, H.; Asami, S.; Toyoda, Y.; Nakai, M.;

(19) van de Loosdrecht, A. A.; Beelen, R. H. J.; Ossenkoppele, G. J.; Broekhoven, M. G; Langenhuijsen, M. M. A. C. *J. Immunol. Methods* **1994**, *174*, 311-320.

(20) Lee, S. H.; Ding, Y.; Yan, X. T.; Kim, Y. H.; Jang, H. D. J. Nat. Prod. 2013, 76, 615-620.

(21) Vichitphan, S.; Vichitphan, K.; Sirikhansaeng, P. *KMITL Sci. Tech. J.* **2007**, *7*, 97-105.

(22) Horikawa, T.; Shimada, T.; Okabe, Y.; Kinoshita, K.; Koyama, K.; Miyamoto, K. I.; Ichinose, K.; Takahashi, K.; Aburada, M. *Biol. Pharm. Bull.* **2012**, *35*, 686-692.

> Received June 10, 2015 Revised July 20, 2015 Accepted July 22, 2015